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RESULTS: Five hundred and ninety eight patients (68.9%
females and 31.3% males) with a mean age of 50 years
were identified. There was a significant difference (p 
0.01) in the age of patients on different medications. Pa-
tients on fluconazole were significantly older compared to
other therapies (p  0.01). The total treatment cost of flu-
conazole was found to be significantly less expensive than
terbinafine, itraconazole and griseofulvin (p  0.01). Sig-
nificant differences in cost prevailed after using analysis of
covariance to remove the bias of age and gender between
the different therapies. It was also found that fluconazole
was more frequently prescribed to patients with poor
health, as identified by total number of different drugs.
The duration of therapy for griseofulvin was significantly
greater (p  0.01) than all other drugs. Forty-two percent
of all therapies were for 30 days or less. Fifty percent re-
ceived therapy for less than 45 days. Only 12% received
therapy for over 120 days. 
CONCLUSION: Age, duration, and costs of therapy are
related to the choice of drug. Additionally, 42% were not
on therapy long enough to have a therapeutic benefit.
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OBJECTIVE: Amphotericin B lipid complex (ABLC) has
been shown to have renal-sparing effects compared to
conventional amphotericin B (AmB). It is unknown,
however, if continued use of ABLC confers any benefit
once a patient requires hemodialysis. The purpose of this
pilot study was to evaluate the outcomes of patients on
hemodialysis who received ABLC. 
METHODS: Patients who received ABLC after initiating
hemodialysis were identified. Variables collected and as-
sessed included patient demographics and clinical character-
istics, indication for ABLC, patient outcomes, and charges. 
RESULTS: A total of 21 patients met our criteria. Over-
all, the mean age was 49 years, and 13 (62%) were male.
Eleven patients had a history of solid organ transplanta-
tion, four had bone marrow transplants, and six had
other medical conditions. The majority of patients had
fungal pathogens identified: six Candida sp., five As-
pergillus sp., four Torulopsis sp. Only seven (33%) pa-
tients were treated with AmB prior to hemodialysis, re-
ceiving a mean eight doses per patient. Eleven patients
were treated with ABLC prior to receiving hemodialysis.
A total of 244 doses of ABLC at a cost of $67,064 were
administered in these 21 patients while concurrently re-
ceiving hemodialysis. Thirteen (62%) of patients died
during that admission while an additional three patients
were dialysis dependent at discharge. Five (24%) patients
were discharged from the hospital off dialysis. Of the five
patients whose renal function recovered, one continued
to receive outpatient antifungal therapy. 
CONCLUSIONS: The majority (76%) of severely ill pa-
tients on hemodialysis receiving ABLC will either die or
remain on dialysis at discharge. A retrospective cohort
study of ABLC versus AmB is planned to determine if
ABLC is cost-effective in patients on hemodialysis.
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SM, a complicated and variable medical decision process,
accounts for a large number of hospitalizations, proce-
dures, and prescriptions. 
OBJECTIVES: The purpose was to develop and validate
a DAF representing current clinical management prac-
tices and outcomes for SM. 
METHODS: An expert panel (EP) comprised of seven
physicians (four pediatric/infectious disease specialists, one
neurologist, one family practitioner, and one emergency
medicine physician) developed and validated the DAF. The
Integrative Group Process (IGP), a modified Delphi tech-
nique, was used with the EP. Seed algorithms based on lit-
erature review were provided to facilitate the discussion.
In a step-by-step process, each panelist confirmed struc-
tural validity and then estimated probability ranges anony-
mously. After the first probability ranges had been identi-
fied, the baselines were determined and complementary
branches were computed and confirmed. Consensus on the
probability ranges was achieved over two rounds of dis-
cussion. A post-meeting follow-up questionnaire con-
firmed agreement with all captured probability estimates. 
RESULTS: Structure validation was achieved by consen-
sus regarding the sequential management of SM. The pri-
mary decision nodes were identified as: empiric antibiotic
use, lumbar puncture (LP), antibiotics post LP, hospital
admission, and post-discharge physician visit. 
CONCLUSIONS: A single DAF can represent current clin-
ical management practices and outcomes for SM for pa-
tients of all ages. The primary drivers in the DAF were an-
tibiotic use and LP leading to the need for hospitalization.
Therapeutic agents to reduce the need for hospitalization
and procedures would significantly impact current man-
